Clin2
NCT06749457Possibly a fitRecruiting

Study of a new drug for healthy adults and kidney patients on dialysis

Staphylococcus Aureus

Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests a new drug called AZD7760 in two groups: healthy adults (Phase I) and adults with end-stage kidney disease who are on hemodialysis through a central venous catheter (Phase IIa). The goal is to see how safe the drug is and how the body processes it. This could lead to a new treatment option for people on dialysis.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
231 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are a healthy adult aged 18 to 55, or an adult aged 18 or older with end-stage kidney disease on hemodialysis.
  • If you have kidney disease, you must use a tunneled central venous catheter for dialysis and have been on dialysis for at least 60 days.
  • You should not have certain serious health conditions like recent infections, cancer, or bleeding disorders.
  • You must be willing to have blood draws and follow study procedures.
  • You cannot be taking long-term antibiotics for a specific type of staph infection (S. aureus) if you are in the kidney disease group.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07228364Recruiting· Phase 1
Testing safety of AZD1613 for polycystic kidney disease

This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.

Birmingham, Alabama
NCT06824987Recruiting· Phase 2
Study of AZD2373 for APOL1-related kidney disease

This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.

Alabaster, Alabama
NCT07000357Recruiting· Phase 3
Study of AZD0780 to reduce heart attack and stroke risk

This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.

Athens, Alabama
NCT07612813Recruiting· Phase 1
Safety study of AZD7760 in healthy Japanese adults

This is a Phase 1 safety study of a new investigational drug called AZD7760 in healthy Japanese volunteers. The trial will test how the body handles the drug and monitor for any side effects.

Sumida-ku
NCT07024823Recruiting· Phase 1
Safety study of AZD4248 in healthy people and those with kidney disease and diabetes

This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.

Glendale, California
NCT03160430Not yet recruiting· Phase 1/Phase 2
Study drug for kidney failure patients on dialysis

This early-phase study tests whether RVX000222 is safe and effective in people with end-stage kidney disease who receive hemodialysis. If you join, you’ll be carefully monitored to see how your body responds and whether it changes kidney-related health measures.

Hear when a new Staphylococcus Aureus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.